- Home
- STRO vs CCEL Comparison
STRO vs CCEL Comparison
Compare STRO & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- CCEL
- Stock Information
- Founded
- STRO 2003
- CCEL 1989
- Country
- STRO United States
- CCEL United States
- Employees
- STRO N/A
- CCEL N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- CCEL Managed Health Care
- Sector
- STRO Health Care
- CCEL Health Care
- Exchange
- STRO Nasdaq
- CCEL Nasdaq
- Market Cap
- STRO 50.0M
- CCEL 51.9M
- IPO Year
- STRO 2018
- CCEL 1997
- Fundamental
- Price
- STRO $0.87
- CCEL $5.05
- Analyst Decision
- STRO Hold
- CCEL Strong Buy
- Analyst Count
- STRO 8
- CCEL 1
- Target Price
- STRO $6.14
- CCEL $8.50
- AVG Volume (30 Days)
- STRO 2.3M
- CCEL 9.9K
- Earning Date
- STRO 05-08-2025
- CCEL 04-15-2025
- Dividend Yield
- STRO N/A
- CCEL 4.96%
- EPS Growth
- STRO N/A
- CCEL N/A
- EPS
- STRO N/A
- CCEL 0.01
- Revenue
- STRO $62,043,000.00
- CCEL $32,102,750.00
- Revenue This Year
- STRO N/A
- CCEL $2.49
- Revenue Next Year
- STRO $1.29
- CCEL $0.95
- P/E Ratio
- STRO N/A
- CCEL $558.76
- Revenue Growth
- STRO N/A
- CCEL 2.33
- 52 Week Low
- STRO $0.52
- CCEL $4.75
- 52 Week High
- STRO $5.17
- CCEL $9.50
- Technical
- Relative Strength Index (RSI)
- STRO 48.53
- CCEL 38.04
- Support Level
- STRO $0.80
- CCEL $4.80
- Resistance Level
- STRO $1.11
- CCEL $5.10
- Average True Range (ATR)
- STRO 0.18
- CCEL 0.29
- MACD
- STRO 0.02
- CCEL -0.00
- Stochastic Oscillator
- STRO 41.53
- CCEL 25.00
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.